WA-TWIN-PROTOCOL
20.6.2024 09:31:27 CEST | Business Wire | Press release
Twin Protocol, a pioneer in the development of ethically engineered, personalized generative artificial intelligence (AI) technology to foster a culture of continuous knowledge sharing, announces a partnership with wellness and tech leaders, Cyberhuman.ai, and Dectec. The three companies are developing cutting-edge solutions that will democratize well-being and guide people around the world on the path of improved health and mindfulness. At the Cannes Creative Festival this week, Dr. Deepak Chopra unveils the first step in this revolutionary approach to sharing well-being knowledge across the globe – his Digital Deepak AI Twin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620183427/en/
Celebrating innovation at Cannes Creative Festival 2024: (pictured from left to right) Bill Inman, CEO of Dectec; Stacey Engle, CEO of Twin Protocol; Deepak Chopra, MD; and Poonacha Machaiah, Co-founder of Cyberhuman.ai., announce the groundbreaking Deepak Chopra AI Twin, a collaboration at the intersection of well-being, AI, and technology. (Photo: Business Wire)
World-renowned pioneer in integrative medicine and personal transformation, Dr. Deepak Chopra previews his digital twin to further his efforts to make chronic disease optional. Digital Deepak is a groundbreaking initiative to integrate advanced technology to more effectively, securely, and personally communicate his timeless wisdom, and guide people along the path of well-being and personal growth.
Interact with Dr. Chopra’s AI Twin here: Digital Deepak. Visitors can ask him questions from a subset of his published books and will even be treated to a sneak peek of his new “Digital Dharma” book, which focuses on the core role of AI in helping individuals achieve well-being and is scheduled for publication in December. Over the coming months, Dr. Chopra’s life’s work will be made available through his digital AI twin.
The partnership between Twin Protocol, Cyberhuman.ai, and Dectec is breaking new ground in the wellness industry. Cyberhuman.ai, an AI platform for personal health and well-being, optimizes lives for peak living at home, work, play, or on the road. The platform uses advanced diagnostics and predictive analytics to provide personalized well-being program recommendations. Dectec is creating the ecosystem and digital wallet that will enable users to make purchases within the ecosystem. Twin Protocol provides the decentralized digital AI twin technology for all healthcare gurus and users, the industry’s most secure, ultra-relatable means of sharing knowledge.
Dr. Chopra’s AI Twin, born out of extensive research and development by Twin Protocol, embodies his vision for guiding individuals on a journey pursuing optimal health and vitality. His AI Twin is poised to revolutionize the future of well-being by offering a holistic approach to wellness that integrates the latest security advancements in AI and blockchain technology. Future updates to the AI Twin will add new communication capabilities and modalities.
Dr. Deepak Chopra shared his perspective on the transformative potential of the AI Twin, stating, “With digital twins and AI technology, it is becoming possible to guide more and more people around the globe on a journey of ever-improving well-being and mindfulness. Over the coming weeks and months, I will share deeper insight through my twin, safely and securely empowering individuals to leverage my assistant as a confidant, health coach, and spiritual guide.”
“The launch of Dr. Deepak Chopra’s AI Twin demonstrates the exceptional vision and capabilities of the Cyberhuman.ai, Dectec, and Twin Protocol team. This is a significant milestone in our journey towards empowering individuals to live their best, most healthy lives,” said Stacey Engle, CEO of Twin Protocol. “By combining cutting-edge technology with his profound wisdom, we are pioneering a new paradigm of well-being that is accessible, personalized, and transformative.”
A unique panel will take place this week at Cannes, exploring the transformative potential of AI and digital twins in enhancing individual well-being.
June 20, 2024
11:00 AM to 12:00 PM
Annex Beach Cannes
Boulevard de la Croisette, Cannes - France
Participants:
- Deepak Chopra – MD
- Poonacha Machaiah – Co-founder, Cyberhuman.ai
- Stacey Engle – CEO, Twin Protocol
- Bill Inman – CEO, Dectec
“AI is reinventing aspects of our world in fundamental ways, including enabling us to create a future where people around the globe can instantly harness the well-being knowledge and insights of global thought leaders such as Dr. Chopra,” said Poonacha Machaiah, co-founder of Cyberhuman.ai. “Through partnerships with world-leading tech innovators like Twin Protocol and Dectec, we are democratizing well-being and helping people live their best lives.”
“When it comes to wellness and health-related information and transactions, its essential that our data is absolutely secure,” said Bill Inman, CEO, Dectec. “With our Web3 platform and collaboration with world-class partners, we’re creating a secure ecosystem that protects users and empowers them to securely manage and improve all aspects of their well-being.”
For more information about Twin Protocol, please visit Twin Protocol.
About Cyberhuman.ai
Cyberhuman.ai is a pioneering advance in personal health and well-being. It is designed as an AI platform to help individuals optimize their lives for peak living across various environments—at home, work, play, or on the road. Leveraging a combination of advanced diagnostics and predictive analytics, the platform offers personalized well-being program recommendations.
About Dectec
Dectec is a pioneering Web3 platform that connects traditional enterprises with advanced AI and blockchain technologies. Specializing in loyalty and rewards programs, Dectec empowers businesses to expand their reach and deepen customer engagement through innovative solutions like user-friendly mobile apps, metaverse experiences, and robotics. The company’s strategy focuses on tapping into new markets with a sophisticated, user-centric wallet system, ensuring clients stay at the forefront of industry innovation for sustained success.
About Twin Protocol
The mission of Twin Protocol’s global venture is to empower individuals and organizations to create secure, dynamic digital versions of themselves to share knowledge, create legacies, and foster continuous learning. Through an advanced AI and blockchain ecosystem, Twin Protocol is revolutionizing the way knowledge and expertise are preserved, shared, and utilized. Twin Protocol, along with strategic partners including SingularityNET, is committed to helping users shape a future where knowledge is an enduring and shared asset. Learn more at Twin Protocol.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620183427/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom